Cargando…

Vitamin E-Loaded PLA- and PLGA-Based Core-Shell Nanoparticles: Synthesis, Structure Optimization and Controlled Drug Release

The (±)-α-Tocopherol (TP) with vitamin E activity has been encapsulated into biocompatible poly(lactic acid) (PLA) and poly(lactide-co-glycolide) (PLGA) carriers, which results in the formation of well-defined nanosized (d ~200–220 nm) core-shell structured particles (NPs) with 15–19% of drug loadin...

Descripción completa

Detalles Bibliográficos
Autores principales: Varga, Norbert, Turcsányi, Árpád, Hornok, Viktória, Csapó, Edit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680571/
https://www.ncbi.nlm.nih.gov/pubmed/31336591
http://dx.doi.org/10.3390/pharmaceutics11070357
_version_ 1783441530832289792
author Varga, Norbert
Turcsányi, Árpád
Hornok, Viktória
Csapó, Edit
author_facet Varga, Norbert
Turcsányi, Árpád
Hornok, Viktória
Csapó, Edit
author_sort Varga, Norbert
collection PubMed
description The (±)-α-Tocopherol (TP) with vitamin E activity has been encapsulated into biocompatible poly(lactic acid) (PLA) and poly(lactide-co-glycolide) (PLGA) carriers, which results in the formation of well-defined nanosized (d ~200–220 nm) core-shell structured particles (NPs) with 15–19% of drug loading (DL%). The optimal ratios of the polymer carriers, the TP active drug as well as the applied Pluronic F127 (PLUR) non-ionic stabilizing surfactant, have been determined to obtain NPs with a TP core and a polymer shell with high encapsulation efficiency (EE%) (69%). The size and the structure of the prepared core-shell NPs as well as the interaction of the carriers and the PLUR with the TP molecules have been determined by transmission electron microscopy (TEM), dynamic light scattering (DLS), infrared spectroscopy (FT-IR) and turbidity studies, respectively. Moreover, the dissolution of the TP from the polymer NPs has been investigated by spectrophotometric measurements. It was clearly confirmed that increase in the EE% from ca. 70% (PLA/TP) to ca. 88% (PLGA65/TP) results in the controlled release of the hydrophobic TP molecules (7 h, PLA/TP: 34%; PLGA75/TP: 25%; PLGA65/TP: 18%). By replacing the PLA carrier to PLGA, ca. 15% more active substance can be encapsulated in the core (PLA/TP: 65%; PLGA65/TP: 80%).
format Online
Article
Text
id pubmed-6680571
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66805712019-08-09 Vitamin E-Loaded PLA- and PLGA-Based Core-Shell Nanoparticles: Synthesis, Structure Optimization and Controlled Drug Release Varga, Norbert Turcsányi, Árpád Hornok, Viktória Csapó, Edit Pharmaceutics Article The (±)-α-Tocopherol (TP) with vitamin E activity has been encapsulated into biocompatible poly(lactic acid) (PLA) and poly(lactide-co-glycolide) (PLGA) carriers, which results in the formation of well-defined nanosized (d ~200–220 nm) core-shell structured particles (NPs) with 15–19% of drug loading (DL%). The optimal ratios of the polymer carriers, the TP active drug as well as the applied Pluronic F127 (PLUR) non-ionic stabilizing surfactant, have been determined to obtain NPs with a TP core and a polymer shell with high encapsulation efficiency (EE%) (69%). The size and the structure of the prepared core-shell NPs as well as the interaction of the carriers and the PLUR with the TP molecules have been determined by transmission electron microscopy (TEM), dynamic light scattering (DLS), infrared spectroscopy (FT-IR) and turbidity studies, respectively. Moreover, the dissolution of the TP from the polymer NPs has been investigated by spectrophotometric measurements. It was clearly confirmed that increase in the EE% from ca. 70% (PLA/TP) to ca. 88% (PLGA65/TP) results in the controlled release of the hydrophobic TP molecules (7 h, PLA/TP: 34%; PLGA75/TP: 25%; PLGA65/TP: 18%). By replacing the PLA carrier to PLGA, ca. 15% more active substance can be encapsulated in the core (PLA/TP: 65%; PLGA65/TP: 80%). MDPI 2019-07-22 /pmc/articles/PMC6680571/ /pubmed/31336591 http://dx.doi.org/10.3390/pharmaceutics11070357 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Varga, Norbert
Turcsányi, Árpád
Hornok, Viktória
Csapó, Edit
Vitamin E-Loaded PLA- and PLGA-Based Core-Shell Nanoparticles: Synthesis, Structure Optimization and Controlled Drug Release
title Vitamin E-Loaded PLA- and PLGA-Based Core-Shell Nanoparticles: Synthesis, Structure Optimization and Controlled Drug Release
title_full Vitamin E-Loaded PLA- and PLGA-Based Core-Shell Nanoparticles: Synthesis, Structure Optimization and Controlled Drug Release
title_fullStr Vitamin E-Loaded PLA- and PLGA-Based Core-Shell Nanoparticles: Synthesis, Structure Optimization and Controlled Drug Release
title_full_unstemmed Vitamin E-Loaded PLA- and PLGA-Based Core-Shell Nanoparticles: Synthesis, Structure Optimization and Controlled Drug Release
title_short Vitamin E-Loaded PLA- and PLGA-Based Core-Shell Nanoparticles: Synthesis, Structure Optimization and Controlled Drug Release
title_sort vitamin e-loaded pla- and plga-based core-shell nanoparticles: synthesis, structure optimization and controlled drug release
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680571/
https://www.ncbi.nlm.nih.gov/pubmed/31336591
http://dx.doi.org/10.3390/pharmaceutics11070357
work_keys_str_mv AT varganorbert vitamineloadedplaandplgabasedcoreshellnanoparticlessynthesisstructureoptimizationandcontrolleddrugrelease
AT turcsanyiarpad vitamineloadedplaandplgabasedcoreshellnanoparticlessynthesisstructureoptimizationandcontrolleddrugrelease
AT hornokviktoria vitamineloadedplaandplgabasedcoreshellnanoparticlessynthesisstructureoptimizationandcontrolleddrugrelease
AT csapoedit vitamineloadedplaandplgabasedcoreshellnanoparticlessynthesisstructureoptimizationandcontrolleddrugrelease